E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Heart Failure with Left Ventricular Ejection Fraction > 40% |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019279 |
E.1.2 | Term | Heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1 To evaluate the effect of AZD4831 on KCCQ-TSS (change from baseline at 16 weeks Part A and change from baseline at 24 weeks Part B) 2 To evaluate the effect of AZD4831 on 6MWD (change from baseline at 16 weeks Part A and change from baseline at 24 weeks Part B) |
|
E.2.2 | Secondary objectives of the trial |
1 To evaluate the effect of AZD4831 on KCCQ-TSS change from baseline at 24 and 48 weeks (Part A) 2 To evaluate the effect of AZD4831 on 6MWD change from baseline at 24 and 48 weeks (Part A) 3 To evaluate the effect of AZD4831 on NT-proBNP (Part A and Part B) 4 To evaluate the effect of AZD4831 on echocardiographic parameter LV-GLS, LAVI, LVMI (Part A) 5 To assess the pharmacokinetics of AZD4831 (Part A and Part B) 6 To evaluate the effect of AZD4831 on inflammatory biomarkers (Part A and Part B) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. ≥ 40 to ≤ 85 years of age, at the time of signing the informed consent. 2. Documented stable symptomatic HF (New York Heart Association Class II-IV) for at least 1 month at Screening (Visit 1) (transient HF in the setting of an MI does not qualify), with a medical history of typical symptoms of HF and receiving optimal therapy for HF as determined by the health-care physician. 3. LVEF > 40% at Screening (Visit 1). All participants will undergo a local echocardiogram at the Screening (Visit 1) with central reading to confirm the LVEF > 40% eligibility criteria before randomisation. 4. 6MWD ≥ 30 meters and ≤ 400 meters at Screening (Visit 1) and Randomisation (Visit 3). Difference in 6MWD between Screening and Randomisation must be < 50 meters. 5. KCCQ-TSS ≤ 90 points at Screening (Visit 1) and Randomisation (Visit 3) 6.NT-proBNP ≥ 250 pg/mL (sinus rhythm) or ≥ 500 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI ≤30 kg/m2. NT-proBNP ≥ 200 pg/mL (sinus rhythm) or ≥ 400 pg/mL (atrial fibrillation/flutter) at Screening (Visit 1) for patients with BMI > 30 kg/m2. The ECG performed at Screening should be used for heart rhythm evaluation. 7.At least one of the following: (a) Structural heart disease, ie, LA enlargement and/or left ventricular hypertrophy at the echocardiogram performed at Screening (Visit 1). Left atrial enlargement is defined by at least 1 of the following: LA width (diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20 cm2 or LA volume ≥ 55 mL or LAVI > 34 mL/m2. Left ventricular hypertrophy is defined by septal thickness or posterior wall thickness ≥ 1.1 cm or LVMI > 95 g/m2 in women and > 115 g/m2 in men. (b) Spectral tissue Doppler echocardiography - E/e’ ratio (average of septal and lateral) ≥ 13 at rest at the echocardiogram performed at Screening (Visit 1). (c) Indirectly estimated elevation of PASP by TRmax velocity > 2.8 m/s (280 cm/s) (PASP > 35 mmHg) at the echocardiogram performed at Screening (Visit 1) OR directly measured pulmonary capillary wedge pressure > 15 mmHg at rest within the past 12 months or > 25 mmHg at exercise documented by right heart catheterisation within 12 months prior to Screening (Visit 1). (d) HF decompensation within 6 months before Randomisation (Visit 3), defined as hospitalisation for HF or IV diuretic treatment for HF during an urgent, unscheduled visit without hospitalisation. 8.Body mass index ≥ 18.0 kg/m2 and ≤ 45.0 kg/m2 9.Male or female of non-childbearing potential. |
|
E.4 | Principal exclusion criteria |
1 eGFR < 30 mL/min/1.73m2 (Chronic Kidney Disease-Epidemiology Collaboration formula) at Screening (Visit 1). 2. Systolic blood pressure < 90 mmHg or ≥ 160 mmHg if not on treatment with ≥ 3 blood pressure lowering medications or ≥ 180 mmHg irrespective of treatments at Randomisation 3. Heart rate > 110 bpm or < 50 bpm at Randomisation 4. Life expectancy < 3 years due to other reasons than cardiovascular disease. 5. History or ongoing allergy/hypersensitivity reactions to drugs (including but not limited to rash, angioedema, acute urticaria). 6. Presence of any disease or condition rather than HF constituting the main reason for limiting the ability to exercise/reduced exercise capacity. 7. Current decompensated HF and/or NT-proBNP > 5000 pg/mL at Screening (Visit 1) 8. Documented history of ejection fraction ≤ 40%.i.e. HF with recovered ejection fraction. Transient ejection fraction decrease e.g. in the setting of an MI does not apply 9. Any planned cardiovascular procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc). 10. Any cardiac event (eg, myocardial infarction, unstable angina), coronary revascularisation (percutaneous coronary intervention or coronary artery bypass grafting), ablation of atrial fibrillation/flutter, valve repair/replacement, implantation of a cardiac resynchronisation therapy device within 12 weeks prior to Screening (Visit 1) or between Screening and Randomisation (Visit 3). 14. Hb < 110 g/L (male) and < 100 g/L (female) or iron-deficiency with/without anaemia requiring ongoing or planned IV iron treatment. 15. Participants with hyperthyroidism, uncontrolled hypothyroidism, or any clinically significant thyroid disease as judged by the investigator. 18. ALT or AST ≥ 2 × ULN at Screening (Visit 1). 19. Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (ie, requiring home oxygen, chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory support within 12 months prior to Screening (Visit 1). 20. Any active infection requiring oral, intravenous or intramuscular treatment. 24. Any concomitant medications known to be a potent CYP3A4 inducers or inhibitors, eg, itraconazole, rifampicin, clarithromycin, or propylthiouracil |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. KCCQ-TSS change from baseline at 16 weeks compared with placebo (Part A) 2. 6MWD change from baseline at 16 weeks compared with placebo (Part A) 3. KCCQ-TSS change from baseline at 24 weeks compared with placebo (Part B) 4. 6MWD change from baseline at 24 weeks compared with placebo (Part B) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1.Baseline to 16 weeks Part A 2.Baseline to 16 weeks Part A 3.Baseline to 24 weeks Part B 4.Baseline to 24 weeks Part B |
|
E.5.2 | Secondary end point(s) |
1. KCCQ-TSS change from baseline at 24 and 48 weeks compared with placebo (Part A) 2. 6MWD change from baseline at 24 and 48 weeks compared with placebo (Part A) 3. NT-proBNP change from baseline at 16, 24, and 48 weeks compared with placebo (Part A) 4. LV-GLS, LAVI, LVMI change from baseline at 16 and 24 weeks compared with placebo (Part A) 5. PK Concentrations will be summarised by timepoints and dose level (Part A) 6. hsCRP and IL-6 change from baseline at 16, 24, and 48 weeks compared with placebo (Part A) 7. NT-proBNP change from baseline at 24 weeks compared with placebo (Part B) 8. hsCRP and IL-6 change from baseline at 24 weeks compared with placebo (Part B) 9. PK Concentrations will be summarised by timepoints and dose level (Part B) 10. To assess the safety and tolerability of AZD4831 as compared with placebo in participants with HF (Part A and Part B). Safety and tolerability will be evaluated in terms of AEs, Vital signs, Clinical laboratory, and ECG. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Baseline to 24 and 48 weeks (Part A) 2. Baseline to 24 and 48 weeks (Part A) 3. Baseline to 16, 24, and 48 weeks (Part A) 4. Baseline to 16 and 24 weeks (Part A) 5 and 9 Summarised by timepoints and dose level (Part A and Part B) 6. Baseline and at 16, 24, and 48 weeks (Part A) 7. Baseline to 24 weeks (Part B) 8. Baseline to 24 weeks (Part B) 10. Change from baseline to end of study (Part A and Part B) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 77 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Canada |
Japan |
Taiwan |
United States |
France |
Poland |
Sweden |
Bulgaria |
Czechia |
Denmark |
Hungary |
Russian Federation |
Slovakia |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date of the last protocol specified visit/assessment (including telephone contact) of the last participant in the study. This would be the last participant in Part B, or Part A (the last Week 52 visit [including telephone contact] for Part A) in the event that Part B is never started. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 5 |